U.S. FDA Approves Yescarta for Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy 08/03/2021 Medications SANTA MONICA, Calif.–(BUSINESS WIRE)–Mar. 5, 2021– Kite, a Gilead Company (Nasdaq: GILD), Read more